Hatakeyama Shuji, Sugaya Norio, Ito Mutsumi, Yamazaki Masahiko, Ichikawa Masataka, Kimura Kazuhiro, Kiso Maki, Shimizu Hideaki, Kawakami Chiharu, Koike Kazuhiko, Mitamura Keiko, Kawaoka Yoshihiro
Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
JAMA. 2007 Apr 4;297(13):1435-42. doi: 10.1001/jama.297.13.1435.
Very little is known about the frequency of generation and transmissibility of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. Furthermore, transmission of resistant virus, whether influenza A or B, has not been recognized to date.
To assess the prevalence and transmissibility of influenza B viruses with reduced sensitivity to neuraminidase inhibitors.
DESIGN, SETTING, AND PATIENTS: Investigation of the neuraminidase inhibitor sensitivity of influenza B isolates from 74 children before and after oseltamivir therapy and from 348 untreated patients with influenza (including 66 adults) seen at 4 community hospitals in Japan during the 2004-2005 influenza season. Four hundred twenty-two viruses from untreated patients and 74 samples from patients after oseltamivir therapy were analyzed.
Sialidase inhibition assay was used to test the drug sensitivities of influenza B viruses. The neuraminidase and hemagglutinin genes of viruses showing reduced sensitivity to neuraminidase inhibitors were sequenced to identify mutations that have the potential to confer reduced sensitivity to these drugs.
In 1 (1.4%) of the 74 children who had received oseltamivir, we identified a variant with reduced drug sensitivity possessing a Gly402Ser neuraminidase substitution. We also identified variants with reduced sensitivity carrying an Asp198Asn, Ile222Thr, or Ser250Gly mutation in 7 (1.7%) of the 422 viruses from untreated patients. Review of the clinical and viral genetic information available on these 7 patients indicated that 4 were likely infected in a community setting, while the remaining 3 were probably infected through contact with siblings shedding the mutant viruses.
In this population, influenza B viruses with reduced sensitivity to neuraminidase inhibitors do not arise as frequently as resistant influenza A viruses. However, they appear to be transmitted within communities and families, requiring continued close monitoring.
对神经氨酸酶抑制剂敏感性降低的乙型流感病毒的产生频率和传播性了解甚少。此外,迄今为止,无论是甲型还是乙型流感病毒,耐药病毒的传播尚未得到确认。
评估对神经氨酸酶抑制剂敏感性降低的乙型流感病毒的流行情况和传播性。
设计、地点和患者:对2004 - 2005年流感季节期间在日本4家社区医院就诊的74名接受奥司他韦治疗前后的儿童以及348名未治疗的流感患者(包括66名成人)的乙型流感病毒分离株进行神经氨酸酶抑制剂敏感性调查。分析了来自未治疗患者的422株病毒和奥司他韦治疗后患者的74份样本。
采用唾液酸酶抑制试验检测乙型流感病毒的药物敏感性。对神经氨酸酶抑制剂敏感性降低的病毒的神经氨酸酶和血凝素基因进行测序,以鉴定可能导致对这些药物敏感性降低的突变。
在74名接受奥司他韦治疗的儿童中,有1名(1.4%)被鉴定出具有药物敏感性降低的变异株,其神经氨酸酶发生了Gly402Ser替换。在未治疗患者的422株病毒中,有7株(1.7%)被鉴定出携带Asp198Asn、Ile222Thr或Ser250Gly突变且敏感性降低的变异株。对这7名患者的临床和病毒基因信息进行回顾表明,其中4名可能是在社区环境中感染的,而其余3名可能是通过接触排出突变病毒的兄弟姐妹而感染的。
在这一人群中,对神经氨酸酶抑制剂敏感性降低的乙型流感病毒不像耐药甲型流感病毒那样频繁出现。然而,它们似乎在社区和家庭中传播,需要持续密切监测。